The Nightview Fund(NITE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NITE The Nightview Fund

休市中 09-18 16:00:00 EDT

39.06

-0.24

-0.62%

盘后38.94

-0.12-0.30%

19:30 EDT

最高39.06	最低38.94	成交量1,792
今开38.94	昨收39.30	日振幅0.30%
总市值3,374万	流通市值3,374万	总股本86.38万
成交额6.98万	换手率0.21%	流通股本86.38万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NITE","market":"US","secType":"STK","nameCN":"The Nightview Fund","latestPrice":39.0583,"timestamp":1789761600000,"preClose":39.3012,"halted":0,"volume":1792,"hourTrading":{"tag":"盘后","latestPrice":38.94,"preClose":39.0583,"latestTime":"19:30 EDT","volume":7,"amount":273.4081,"timestamp":1789774205590,"change":-0.1183,"changeRate":-0.003029,"amplitude":0},"delay":0,"changeRate":-0.0061804728608795345,"floatShares":863800,"shares":863800,"eps":0,"marketStatus":"休市中","change":-0.2429,"latestTime":"09-18 16:00:00 EDT","open":38.94,"high":39.0583,"low":38.94,"amount":69821.9648,"amplitude":0.00301,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1506571200000,"exchange":"ARCA","adjPreClose":39.3012,"sharesOutstanding":803768,"nav":39.28,"aum":33930011.27,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.94,"preClose":39.0583,"latestTime":"19:30 EDT","volume":7,"amount":273.4081,"timestamp":1789774205590,"change":-0.1183,"changeRate":-0.003029,"amplitude":0},"volumeRatio":4.969497352813652},"requestUrl":"/m/hq/s/NITE","defaultTab":"news","newsList":[{"id":"2663045518","title":"新股消息｜FronteraTherapeutics再次递表港交所，深耕rAAV眼科基因治疗赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663045518","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663045518?lang=zh_cn&edition=full","pubTime":"2026-08-30 09:27","pubTimestamp":1788053221,"startTime":"0","endTime":"0","summary":"　　据招股书，该公司于2019年注册成立，是一家临床阶段基因疗法公司，致力于自主开发重组腺相关病毒基因疗法。Frontera公司的管线尤其专注于眼科及心血管疾病。　　截至最后实际可行日期，有超过 250 种在研 rAAV 基因治疗药物，其中五种处于 BLA 阶段。罕见病及眼科疾病占全球 rAAV 基因治疗管线的大部分。罕见病治疗占所有在研 rAAV 基因治疗药物的一半以上。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260830/32353638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["NITE","IPOS","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663045362","title":"新股消息｜FronteraTherapeutics再次递表港交所，深耕rAAV眼科基因治疗赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663045362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663045362?lang=zh_cn&edition=full","pubTime":"2026-08-30 08:51","pubTimestamp":1788051069,"startTime":"0","endTime":"0","summary":"Frontera公司的管线尤其专注于眼科及心血管疾病。截至最后实际可行日期，FronteraTherapeutics 尚未取得任何候选药物的上市批准，也未从产品销售中产生任何收入。罕见病及眼科疾病占全球rAAV基因治疗管线的大部分。罕见病治疗占所有在研rAAV基因治疗药物的一半以上。董事会资料FronteraTherapeutics 董事会由九名董事组成，包括一名执行董事、五名非执行董事及三名独立非执行董事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NITE","HEXmain","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661759472","title":"REGENXBIO股价盘前下跌25%，因美国FDA暂停该公司针对亨特综合征的基因疗法临床试验。","url":"https://stock-news.laohu8.com/highlight/detail?id=2661759472","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661759472?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:42","pubTimestamp":1787571759,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","NITE","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660378334","title":"火箭实验室加入美国太空部队价值 9.81 亿美元的 NITE‑STAR 项目，推进太空测试与训练基础设施建设。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660378334","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660378334?lang=zh_cn&edition=full","pubTime":"2026-08-18 05:11","pubTimestamp":1787001077,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XLII","BK4588","AIRR","MADE","PRN","NITE","XLI","BK4581","HWAY","BK4585","BK4550","NFRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nightstartx.com","stockEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1548},{"period":"1year","weight":0.1051},{"period":"ytd","weight":0.0668}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nightstar Therapeutics Plc最初于2013年5月根据英格兰和威尔士的法律成立，随后于2014年1月更名为NightstaRx Limited。该公司是一家领先的临床阶段基因治疗公司，专注于开发和治疗药物患有罕见的遗传性视网膜疾病，否则会进入失明。利用他们在眼科，基因治疗和药物开发方面的专业知识，他们正在开发一系列专有产品候选人，旨在大幅度修改或停止目前尚未批准的治疗的遗传性视网膜疾病的进展。他们的任务是维护和通过构建领先的垂直整合视网膜基因治疗公司，恢复患者的视力。","exchange":"ARCA","name":"The Nightview Fund","nameEN":"The Nightview Fund"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"The Nightview Fund(NITE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供The Nightview Fund(NITE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"The Nightview Fund,NITE,The Nightview Fund股票,The Nightview Fund股票老虎,The Nightview Fund股票老虎国际,The Nightview Fund行情,The Nightview Fund股票行情,The Nightview Fund股价,The Nightview Fund股市,The Nightview Fund股票价格,The Nightview Fund股票交易,The Nightview Fund股票购买,The Nightview Fund股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"The Nightview Fund(NITE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供The Nightview Fund(NITE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}